Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Dorzolamide; Maleic acid; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

1. Age: 30 years or older.

2. Primary open-angle glaucoma (POAG) or ocular hypertensive in at least one eye.

3. Best corrected visual acuity at least 20/40 in at least one eye.

Exclusion Criteria:

1. History of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy.

2. History of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis).

3. History or signs of intraocular trauma.

4. Any abnormality preventing reliable applanation tonometry.

5. Current use of any ophthalmic or systemic steroid which may interfere with this investigation.

6. Severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.